NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market Wednesday that its second quarter revenues rose 6 percent compared to Q2 of 2015.

For the period ended Jan. 31, 2015, the company reported total revenues of $24.6 million, up from $23.1 million in Q2 of 2015. Clinical lab services revenues rose 19 percent to $17.5 million from $14.7 million a year ago. The company credited increased demand for molecular diagnostics testing at higher reimbursement rates for the increase.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.